Tacrograf 1mg Capsule 1 Strip

✔️ Dosage & Administration: General Guidelines:

• Administer orally every 12 hours.
• Begin the initial dose 6 hours after transplantation for liver, heart, or lung transplants.
• For kidney transplants, administer within 24 hours of transplantation after ensuring renal function recovery.
• Target trough concentrations of tacrolimus in the blood should guide dose adjustments.

✔️ Important Notes:

• Use of tacrolimus should be individualized based on transplant type, patient condition, and concurrent immunosuppressive therapy.
• Patients with hepatic or renal impairment may require dose modifications.
• Consult your physician for detailed guidance based on the specific transplant scenario.

✔️ Dosage for Adults:

Note: Patients with cystic fibrosis undergoing lung transplants may require higher doses due to reduced bioavailability. Monitor trough levels closely.

✔️ Dosage for Pediatric Patients:

Note: Like adults, pediatric cystic fibrosis patients undergoing lung transplants may require dose adjustments due to reduced bioavailability.

✔️ Monitoring and Adjustments:

• Monitor whole blood trough concentrations regularly to ensure therapeutic efficacy and minimize toxicity.
• Adjust doses based on the patient’s clinical response, drug levels, and side effects.

✔️ Common adverse reactions (≥15%):

• Renal: Abnormal renal function, nephrotoxicity.
• Metabolic: Hyperglycemia, diabetes mellitus, hyperlipemia, hyperkalemia, hypomagnesemia.
• Cardiovascular: Hypertension, pericardial effusion.
• Infections: CMV infection, urinary tract infection, bronchitis.
• Neurological: Tremor, headache, paresthesia, insomnia, neurotoxicity (e.g., PRES).
• GI: Constipation, diarrhea, nausea, abdominal pain.
• Hematologic: Leukopenia, anemia.
• Other: Fever, peripheral edema.

✔️ Drug Interactions:

Mycophenolic Acid (MPA) Products:

• Tacrograf can increase MPA exposure after switching from cyclosporine.
• Recommendation: Monitor for MPA-related adverse reactions and adjust the dose of MMF (mycophenolate mofetil) or MPA accordingly.

Nelfinavir and Grapefruit Juice:

• Both inhibit CYP3A enzymes, increasing tacrolimus concentrations.
• Recommendation: Avoid concomitant use.

CYP3A Inhibitors:

• Increase tacrolimus concentrations.
• Recommendation: Monitor tacrolimus levels and adjust the dose as necessary.

CYP3A4 Inducers:

• Decrease tacrolimus concentrations.
• Recommendation: Monitor tacrolimus levels and adjust the dose accordingly.

Cannabidiol (CBD):

• May require therapeutic drug monitoring and potential dose reduction for Tacrograf.

✔️ Contraindications:

• Hypersensitivity:
  • To tacrolimus or HCO-60 (polyoxyl 60 hydrogenated castor oil).

✔️ Overdose Effects:

• Acute overdose symptoms:
  • Tremors, abnormal renal function, hypertension, peripheral edema.
• Treatment:
  • General supportive care and symptom management.
  • Activated charcoal has been used, but its efficacy is not well-established.

✔️ Pregnancy & Lactation:

1. Pregnancy:
   • Tacrograf can cause fetal harm.
   • Advice: Inform pregnant women of potential risks.
2. Lactation:
   • Insufficient data; use caution and consult with a physician.

✔️ Precautions & Warnings:

Not Interchangeable:

• Extended-release Tacrograf formulations differ; ensure correct medication is administered.

New Onset Diabetes After Transplant (NODAT):

• Recommendation: Monitor blood glucose levels post-transplant.

Nephrotoxicity:

• Risk of acute or chronic renal impairment.
• Action: Reduce dose and monitor kidney function.

Neurotoxicity:

• May cause Posterior Reversible Encephalopathy Syndrome (PRES) or other neurologic abnormalities.
• Action: Reduce or discontinue Tacrograf if symptoms occur.

Hyperkalemia:

• Monitor serum potassium; use caution with other hyperkalemia-inducing drugs.

Hypertension:

• Management: Use antihypertensive therapy as needed while monitoring drug-drug interactions.

Anaphylaxis (IV Formulation):

• Risk of anaphylactic reactions.
• Action: Observe patients closely during IV administration.

Not Recommended with Sirolimus:

• Increases risk of serious adverse reactions in liver and heart transplants.

Myocardial Hypertrophy:

• Action: Consider reducing or discontinuing dose in case of cardiac complications.

Immunizations:

• Avoid live vaccines during therapy.

Pure Red Cell Aplasia (PRCA):

• Action: Consider discontinuing Tacrograf.

Thrombotic Microangiopathy (TMA):

• Includes Hemolytic Uremic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP).
• Action: Monitor for symptoms, especially with infections or certain medications.

✔️ Storage Conditions:

• Store below 30°C in a dry place, away from light and moisture.
• Keep out of the reach of children.